Developer docs
API playgroundTry for free, no card

Search company profiles

ALZpath

Full company profile

uuid00065i7

Namestring
ALZpath
Legal namestring
ALZpath, Inc.
Websiteurl
alzpath.bio
Company typeenum
Private
Founded yearint
2020
Descriptiontext

ALZpath, Inc. is a privately held diagnostics company founded in 2020 in Carlsbad, California, focused on blood-based detection of Alzheimer's disease pathology. Its core asset is a proprietary monoclonal antibody targeting phosphorylated tau 217 (pTau217), an early protein biomarker that the company and independent studies have shown rises in blood up to 15 years before cognitive symptoms appear. The antibody is offered as a Research Use Only (RUO) reagent and is licensed to leading in vitro diagnostic (IVD) companies — Abbott, Roche, Siemens Healthineers, Beckman Coulter, Quanterix, Bio-Techne, and Alamar Biosciences — for integration into their respective immunoassay platforms (Alinity ci-series, Elecsys, Atellica, DxI, Simoa, Ella/Simple Plex, and NULISA). Performance has been independently validated at AUC 0.92–0.97 across cohorts, with reported 98.2% sensitivity and 95% PPV/NPV at relevant cut-offs.

ALZpath's commercial model rests on three pillars: (1) antibody licensing and royalties from IVD partners developing commercial assays, (2) RUO reagent sales to academic and pharmaceutical researchers, and (3) a clinical testing service via the ALZpathDx laboratory developed test (LDT), offered through CAP/CLIA-certified partner Neurocode at $349 per test on a patient-pay basis (no CPT code in place; a PLA code exists). Go-to-market is partnership-driven and evidence-led: the company cites 200+ peer-reviewed publications across 18 countries, 157 conference posters/presentations, and validation studies including a December 2025 Nature paper analyzing 11,000+ samples. It pursues recognition through scientific channels rather than traditional sales, with award validation including TIME Best Inventions 2024, Fast Company Most Innovative Companies 2025, Edison Bronze, and BioTech Breakthrough Diagnostics Innovation of the Year 2025.

The company targets three primary user groups: clinicians and healthcare systems seeking non-invasive, scalable Alzheimer's detection to replace or triage PET imaging and lumbar punctures; pharmaceutical companies and academic researchers using pTau217 in clinical-trial enrollment, endpoint assessment, and biomarker discovery; and patients/caregivers seeking earlier answers. The total addressable market — global blood-based Alzheimer's biomarkers — is projected at $654.4M by 2035 (15.1% CAGR from 2025). Headcount is reported at 11–50 employees, and the company is led by CEO Mike Banville (appointed January 2025), with scientific co-founder Eric Reiman (CEO of Banner Alzheimer's Institute) and co-founder/chair Jerre Stead. Funding to date consists of an undisclosed grant from the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (July 2023); no revenue has been disclosed.

Short descriptiontext

ALZpath, founded in 2020 in Carlsbad, California, develops a proprietary monoclonal pTau217 antibody that enables blood-based detection of Alzheimer's disease pathology, licensing it to major IVD companies (Abbott, Roche, Siemens, Beckman Coulter) and offering an LDT through Neurocode for clinicians and researchers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCarlsbad, United States
HQ citystring
Carlsbad
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
blood-based diagnostics, Alzheimer's diagnostics, monoclonal antibody technology, biomarker assay development, diagnostic antibody licensing
Industry2 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Alzheimer's Disease Diagnostics
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Antibody Licensing
TypeLicensing Royalties
Description

ALZpath licenses its proprietary pTau217 antibody to diagnostic companies for development and commercialization of in vitro diagnostic tests. Licensing agreements with Abbott, Roche, Siemens Healthineers, Beckman Coulter Diagnostics, Bio-Techne, Alamar Biosciences, and Quanterix generate licensing fees and ongoing royalties.

alzpath.bio
2Laboratory Developed Test (LDT) Services
TypeOne Time License
Description

ALZpathDx test available through Neurocode laboratory as a CLIA-certified laboratory developed test, providing direct revenue from clinical testing services.

alzpath.bio
3Grant Funding
TypeLicensing Royalties
Description

Received undisclosed funding from Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator for development and clinical validation of blood-based diagnostic assay.

finsmes.com
4Research Use Only (RUO) Reagent Sales
TypeLicensing Royalties
Description

The pTau217 antibody is available as Research Use Only reagent for researchers and diagnostic developers through direct partnerships and platform licensing arrangements.

alzpath.bio
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels9 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Technology or R&D, Personnel
Pricing details1 tier
1ALZpathDx Laboratory Developed Test
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

$349 per test through Neurocode laboratory. Test must be ordered by a physician for individuals 55+ experiencing cognitive decline.

alzpath.bio
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ALZpath develops and commercializes a proprietary monoclonal pTau217 antibody that enables blood-based detection of Alzheimer's disease pathology up to 15 years before symptoms appear. The company licenses this antibody to leading in vitro diagnostic companies (Abbott, Roche, Siemens Healthineers, Beckman Coulter) for integration into their immunoassay platforms, and offers ALZpathDx as a laboratory developed test through Neurocode. The antibody achieves AUC values of 0.92-0.97 for detecting amyloid and tau pathology, matching the performance of PET imaging and cerebrospinal fluid testing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • AUC 0.92-0.97 for amyloid and tau detection across independent cohorts
+5 more records
Product overview1 text field

ALZpath offers a focused diagnostic portfolio centered on its proprietary pTau217 monoclonal antibody, which serves as the core technology powering blood-based Alzheimer's disease detection. The company's flagship product is the ALZpath pTau217 Antibody—a research-use and diagnostic-grade reagent that detects phosphorylated tau 217, one of the earliest biomarkers of Alzheimer's pathology, enabling detection up to 15 years before symptoms appear. This antibody is licensed to leading diagnostic companies including Abbott, Roche, Beckman Coulter Diagnostics, Siemens Healthineers, Alamar Biosciences, Bio-Techne, and Quanterix for integration into their respective testing platforms (Alinity ci-series, Elecsys, DxI, Atellica, NULISA, Ella/Simple Plex, and Simoa). For direct clinical access, ALZpath offers ALZpathDx, a laboratory developed test (LDT) available through CLIA-certified partner Neurocode, providing blood-based pTau217 testing for patients with cognitive concerns. The company is pursuing FDA clearance for its assays as In Vitro Diagnostics (IVDs).

Product and service2 records
1ALZpath pTau217 Antibody
CategoryDiagnostic Reagent / Antibody
Description

A proprietary monoclonal antibody that detects phosphorylated tau 217 (pTau217), a key protein biomarker of Alzheimer's disease pathology. The antibody serves as the scientific foundation for blood-based Alzheimer's diagnostic tests and is licensed to leading diagnostic companies for integration into their immunoassay platforms (Abbott Alinity ci-series, Roche Elecsys, Siemens Atellica, Beckman Coulter DxI, Quanterix Simoa, Bio-Techne Ella, and Alamar NULISA).

2ALZpathDx
CategoryClinical Diagnostic Test
Description

A blood-based laboratory developed test (LDT) using the ALZpath pTau217 antibody to detect Alzheimer's disease pathology through measurement of pTau217 protein levels in EDTA plasma. Available through Neurocode, a CAP/CLIA certified partner laboratory, for individuals 55 and older experiencing cognitive decline; ordered by a physician at $349 per test. Currently not FDA approved; available as LDT only.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1Abbott
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-06-24
Description

Global licensing agreement to incorporate ALZpath's proprietary pTau217 antibody into Abbott's in vitro diagnostic test for Alzheimer's disease, designed for use on Abbott's Alinity ci-series systems representing one of the largest install bases of immunoassay instruments worldwide.

prnewswire.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-12-15
Description

Licensing agreement for Siemens Healthineers to utilize ALZpath's pTau217 antibody in development of pTau217 assay for Atellica immunoassay systems, expanding global access to Alzheimer's diagnostic testing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-18
Description

Strategic partnership to advance neurodegenerative disease research utilizing pTau217 antibody on Bio-Techne's Ella/Simple Plex immunoassay platform.

4Beckman Coulter Diagnostics
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-07-15
Description

Licensing agreement to provide proprietary pTau217 antibody for development of diagnostic blood test for Alzheimer's disease on Beckman Coulter's DxI series immunoassay platform.

alzpath.bio
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-06-10
Description

Licensing agreement for use of ALZpath's proprietary pTau217 antibody in blood test to diagnose Alzheimer's disease, utilizing Roche's Elecsys immunoassay platform.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-02-29
Description

Strategic supply agreement for pTau217 antibody to advance Alzheimer's disease research using Alamar's NULISA ultra-sensitive proteomics platform.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Platform partnership for integration of pTau217 antibody into Quanterix's Simoa HD-X (and SR-X) immunoassay platform enabling ultra-sensitive detection of pTau217 in research settings.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

CAP/CLIA certified laboratory partnership offering ALZpathDx test, the first LDT using the ALZpath antibody, available across the United States for clinical diagnosis of Alzheimer's disease.

Strategic tierSupportingTypeTechnology or Integration
Description

Partnered with Eli Lilly for Alzheimer's blood test development as part of Fast Company's Most Innovative Companies feature.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Research collaboration with Banner Alzheimer's Institute, a leader in Alzheimer's prevention research, as part of extensive academic partnership network including ADNI, University of Gothenburg, and others.

11ADNI (Alzheimer's Disease Neuroimaging Initiative)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Collaboration as part of the ADNI consortium contributing to Alzheimer's research biomarker standardization and clinical validation studies.

alzpath.bio
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

C2N Diagnostics offers PrecivityAD, a blood-based Alzheimer's diagnostic test measuring amyloid probability via mass spectrometry. It is the most direct competitor to ALZpath's ALZpathDx LDT, addressing the same clinical use case for patients with cognitive concerns.

TypeDirect peer
Description

Fujirebio has FDA Breakthrough Device Designation for the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, the most clinically advanced blood-based AD IVD. They compete head-to-head with ALZpath-licensed assays being developed on Roche/Siemens/Beckman platforms.

TypeDirect peer
Description

Quanterix operates the Simoa HD-X ultra-sensitive immunoassay platform and is both an ALZpath licensing partner and a potential competitor in the research-use biomarker space. Comparable in offering ultra-sensitive blood-based neurology biomarker detection.

TypeBroad incumbent
Description

Eli Lilly has internal pTau217 assay development capabilities (Jeff Dage pioneered p-tau assays at Lilly for 20+ years) and is also a partnered company of ALZpath. As the developer of Kisunla and a major AD therapeutics player, Lilly is both a customer and a potential competitor for AD diagnostics.

TypeBroad incumbent
Description

Roche is an ALZpath licensing partner for the Elecsys platform but also operates the world's largest immunoassay installed base and has internal biomarker development capabilities. As a broad IVD incumbent, Roche is both ALZpath's largest near-term revenue opportunity and its most capable long-term competitor.

TypeEmerging player
Description

Sysmex has developed the HISCL series of fully automated immunoassay analyzers and is actively pursuing Alzheimer's blood-based diagnostics. They represent an emerging IVD platform competitor pursuing the same clinical market as ALZpath-licensed assays.

TypeDirect peer
Description

Araclon Biotech (subsidiary of Grifols) develops the ABtest for amyloid-beta blood-based detection in Alzheimer's. It is a direct competitor to ALZpath's pTau217-based approach for blood-based AD pathology detection.

8ADx NeuroSciences
TypeEmerging player
Description

ADx NeuroSciences is a biomarker-focused company developing assays and reagents for neurodegenerative disease diagnostics. It operates in the same antibody/biomarker infrastructure layer as ALZpath and supplies major IVD players including Fujirebio.

TypeEmerging player
Description

MagQu develops immunomagnetic reduction (IMR) technology for ultra-sensitive blood-based detection of biomarkers including those for Alzheimer's disease (e.g., Aβ42, tau). Comparable as an emerging diagnostic technology platform targeting the same AD blood-test market.

TypeOthers
Description

Bio-Techne is both an ALZpath licensing partner (Ella/Simple Plex platform) and a major supplier of research-use-only antibodies and immunoassay reagents. It functions as a complementary ecosystem participant rather than a direct diagnostic competitor.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ALZpath

Alzheimer's Disease Diagnosticsalzpath.bio

ALZpath, founded in 2020 in Carlsbad, California, develops a proprietary monoclonal pTau217 antibody that enables blood-based detection of Alzheimer's disease pathology, licensing it to major IVD companies (Abbott, Roche, Siemens, Beckman Coulter) and offering an LDT through Neurocode for clinicians and researchers.

What ALZpath does

ALZpath, Inc. is a privately held diagnostics company founded in 2020 in Carlsbad, California, focused on blood-based detection of Alzheimer's disease pathology. Its core asset is a proprietary monoclonal antibody targeting phosphorylated tau 217 (pTau217), an early protein biomarker that the company and independent studies have shown rises in blood up to 15 years before cognitive symptoms appear. The antibody is offered as a Research Use Only (RUO) reagent and is licensed to leading in vitro diagnostic (IVD) companies — Abbott, Roche, Siemens Healthineers, Beckman Coulter, Quanterix, Bio-Techne, and Alamar Biosciences — for integration into their respective immunoassay platforms (Alinity ci-series, Elecsys, Atellica, DxI, Simoa, Ella/Simple Plex, and NULISA). Performance has been independently validated at AUC 0.92–0.97 across cohorts, with reported 98.2% sensitivity and 95% PPV/NPV at relevant cut-offs.

ALZpath's commercial model rests on three pillars: (1) antibody licensing and royalties from IVD partners developing commercial assays, (2) RUO reagent sales to academic and pharmaceutical researchers, and (3) a clinical testing service via the ALZpathDx laboratory developed test (LDT), offered through CAP/CLIA-certified partner Neurocode at $349 per test on a patient-pay basis (no CPT code in place; a PLA code exists). Go-to-market is partnership-driven and evidence-led: the company cites 200+ peer-reviewed publications across 18 countries, 157 conference posters/presentations, and validation studies including a December 2025 Nature paper analyzing 11,000+ samples. It pursues recognition through scientific channels rather than traditional sales, with award validation including TIME Best Inventions 2024, Fast Company Most Innovative Companies 2025, Edison Bronze, and BioTech Breakthrough Diagnostics Innovation of the Year 2025.

The company targets three primary user groups: clinicians and healthcare systems seeking non-invasive, scalable Alzheimer's detection to replace or triage PET imaging and lumbar punctures; pharmaceutical companies and academic researchers using pTau217 in clinical-trial enrollment, endpoint assessment, and biomarker discovery; and patients/caregivers seeking earlier answers. The total addressable market — global blood-based Alzheimer's biomarkers — is projected at $654.4M by 2035 (15.1% CAGR from 2025). Headcount is reported at 11–50 employees, and the company is led by CEO Mike Banville (appointed January 2025), with scientific co-founder Eric Reiman (CEO of Banner Alzheimer's Institute) and co-founder/chair Jerre Stead. Funding to date consists of an undisclosed grant from the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (July 2023); no revenue has been disclosed.

ALZpath firmographics

Firmographics
Name
ALZpath
Legal name
ALZpath, Inc.
Website
https://alzpath.bio
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
ALZpath, founded in 2020 in Carlsbad, California, develops a proprietary monoclonal pTau217 antibody that enables blood-based detection of Alzheimer's disease pathology, licensing it to major IVD companies (Abbott, Roche, Siemens, Beckman Coulter) and offering an LDT through Neurocode for clinicians and researchers.
Ownership category
akta.pro rank

ALZpath industry classification

Industry
Product category
Alzheimer's Disease Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Blood-based diagnostics
  • Alzheimer's diagnostics
  • Monoclonal antibody technology
  • Biomarker assay development
  • Diagnostic antibody licensing

Where ALZpath is headquartered

Location

Headquarters

HQ city
Carlsbad
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ALZpath business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel

Revenue model

  1. Antibody Licensing: ALZpath licenses its proprietary pTau217 antibody to diagnostic companies for development and commercialization of in vitro diagnostic tests. Licensing agreements with Abbott, Roche, Siemens Healthineers, Beckman Coulter Diagnostics, Bio-Techne, Alamar Biosciences, and Quanterix generate licensing fees and ongoing royalties.
  2. Laboratory Developed Test (LDT) Services: ALZpathDx test available through Neurocode laboratory as a CLIA-certified laboratory developed test, providing direct revenue from clinical testing services.
  3. Grant Funding: Received undisclosed funding from Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator for development and clinical validation of blood-based diagnostic assay.
  4. Research Use Only (RUO) Reagent Sales: The pTau217 antibody is available as Research Use Only reagent for researchers and diagnostic developers through direct partnerships and platform licensing arrangements.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goALZpathDx Laboratory Developed Test

Go-to-market motion3 records

Distribution channels9 records

Marketing channels8 records

ALZpath product offering

Product offering

Core offering

ALZpath develops and commercializes a proprietary monoclonal pTau217 antibody that enables blood-based detection of Alzheimer's disease pathology up to 15 years before symptoms appear. The company licenses this antibody to leading in vitro diagnostic companies (Abbott, Roche, Siemens Healthineers, Beckman Coulter) for integration into their immunoassay platforms, and offers ALZpathDx as a laboratory developed test through Neurocode. The antibody achieves AUC values of 0.92-0.97 for detecting amyloid and tau pathology, matching the performance of PET imaging and cerebrospinal fluid testing.

Product overview

ALZpath offers a focused diagnostic portfolio centered on its proprietary pTau217 monoclonal antibody, which serves as the core technology powering blood-based Alzheimer's disease detection. The company's flagship product is the ALZpath pTau217 Antibody—a research-use and diagnostic-grade reagent that detects phosphorylated tau 217, one of the earliest biomarkers of Alzheimer's pathology, enabling detection up to 15 years before symptoms appear. This antibody is licensed to leading diagnostic companies including Abbott, Roche, Beckman Coulter Diagnostics, Siemens Healthineers, Alamar Biosciences, Bio-Techne, and Quanterix for integration into their respective testing platforms (Alinity ci-series, Elecsys, DxI, Atellica, NULISA, Ella/Simple Plex, and Simoa). For direct clinical access, ALZpath offers ALZpathDx, a laboratory developed test (LDT) available through CLIA-certified partner Neurocode, providing blood-based pTau217 testing for patients with cognitive concerns. The company is pursuing FDA clearance for its assays as In Vitro Diagnostics (IVDs).

Differentiator

Problem solved

Functional benefit

Products and services

  • ALZpath pTau217 Antibody A proprietary monoclonal antibody that detects phosphorylated tau 217 (pTau217), a key protein biomarker of Alzheimer's disease pathology. The antibody serves as the scientific foundation for blood-based Alzheimer's diagnostic tests and is licensed to leading diagnostic companies for integration into their immunoassay platforms (Abbott Alinity ci-series, Roche Elecsys, Siemens Atellica, Beckman Coulter DxI, Quanterix Simoa, Bio-Techne Ella, and Alamar NULISA).
  • ALZpathDx A blood-based laboratory developed test (LDT) using the ALZpath pTau217 antibody to detect Alzheimer's disease pathology through measurement of pTau217 protein levels in EDTA plasma. Available through Neurocode, a CAP/CLIA certified partner laboratory, for individuals 55 and older experiencing cognitive decline; ordered by a physician at $349 per test. Currently not FDA approved; available as LDT only.

Quantifiable outcome

  • AUC 0.92-0.97 for amyloid and tau detection across independent cohorts
  • +5 more outcomes

Companies that use ALZpath

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles3 records

ALZpath technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability1 record

Feature5 records

ALZpath partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and supporting.

  • AbbottcoreOEM/ Whitelabel/ Licensing Partner · 24 June 2026Global licensing agreement to incorporate ALZpath's proprietary pTau217 antibody into Abbott's in vitro diagnostic test for Alzheimer's disease, designed for use on Abbott's Alinity ci-series systems representing one of the largest install bases of immunoassay instruments worldwide.
  • Siemens HealthineerscoreOEM/ Whitelabel/ Licensing Partner · 15 December 2025Licensing agreement for Siemens Healthineers to utilize ALZpath's pTau217 antibody in development of pTau217 assay for Atellica immunoassay systems, expanding global access to Alzheimer's diagnostic testing.
  • Bio-TechnecoreStrategic or Co-development Partner · 18 November 2024Strategic partnership to advance neurodegenerative disease research utilizing pTau217 antibody on Bio-Techne's Ella/Simple Plex immunoassay platform.
  • Beckman Coulter DiagnosticscoreOEM/ Whitelabel/ Licensing Partner · 15 July 2024Licensing agreement to provide proprietary pTau217 antibody for development of diagnostic blood test for Alzheimer's disease on Beckman Coulter's DxI series immunoassay platform.
  • RochecoreOEM/ Whitelabel/ Licensing Partner · 10 June 2024Licensing agreement for use of ALZpath's proprietary pTau217 antibody in blood test to diagnose Alzheimer's disease, utilizing Roche's Elecsys immunoassay platform.
  • Alamar BiosciencessupportingStrategic or Co-development Partner · 29 February 2024Strategic supply agreement for pTau217 antibody to advance Alzheimer's disease research using Alamar's NULISA ultra-sensitive proteomics platform.
  • QuanterixcoreOEM/ Whitelabel/ Licensing PartnerPlatform partnership for integration of pTau217 antibody into Quanterix's Simoa HD-X (and SR-X) immunoassay platform enabling ultra-sensitive detection of pTau217 in research settings.
  • NeurocodecoreImplementation/ SI/ Consulting PartnerCAP/CLIA certified laboratory partnership offering ALZpathDx test, the first LDT using the ALZpath antibody, available across the United States for clinical diagnosis of Alzheimer's disease.
  • Eli LillysupportingTechnology or IntegrationPartnered with Eli Lilly for Alzheimer's blood test development as part of Fast Company's Most Innovative Companies feature.
  • Banner Alzheimer's InstitutesupportingStrategic or Co-development PartnerResearch collaboration with Banner Alzheimer's Institute, a leader in Alzheimer's prevention research, as part of extensive academic partnership network including ADNI, University of Gothenburg, and others.
  • ADNI (Alzheimer's Disease Neuroimaging Initiative)supportingStrategic or Co-development PartnerCollaboration as part of the ADNI consortium contributing to Alzheimer's research biomarker standardization and clinical validation studies.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

ALZpath competitors and assessment

Company assessment

Direct peers

  • C2N Diagnostics: C2N Diagnostics offers PrecivityAD, a blood-based Alzheimer's diagnostic test measuring amyloid probability via mass spectrometry. It is the most direct competitor to ALZpath's ALZpathDx LDT, addressing the same clinical use case for patients with cognitive concerns.
  • Fujirebio: Fujirebio has FDA Breakthrough Device Designation for the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, the most clinically advanced blood-based AD IVD. They compete head-to-head with ALZpath-licensed assays being developed on Roche/Siemens/Beckman platforms.
  • Quanterix: Quanterix operates the Simoa HD-X ultra-sensitive immunoassay platform and is both an ALZpath licensing partner and a potential competitor in the research-use biomarker space. Comparable in offering ultra-sensitive blood-based neurology biomarker detection.
  • Araclon Biotech (Grifols): Araclon Biotech (subsidiary of Grifols) develops the ABtest for amyloid-beta blood-based detection in Alzheimer's. It is a direct competitor to ALZpath's pTau217-based approach for blood-based AD pathology detection.

Broad incumbents

  • Eli Lilly: Eli Lilly has internal pTau217 assay development capabilities (Jeff Dage pioneered p-tau assays at Lilly for 20+ years) and is also a partnered company of ALZpath. As the developer of Kisunla and a major AD therapeutics player, Lilly is both a customer and a potential competitor for AD diagnostics.
  • Roche Diagnostics: Roche is an ALZpath licensing partner for the Elecsys platform but also operates the world's largest immunoassay installed base and has internal biomarker development capabilities. As a broad IVD incumbent, Roche is both ALZpath's largest near-term revenue opportunity and its most capable long-term competitor.

Emerging players

  • Sysmex: Sysmex has developed the HISCL series of fully automated immunoassay analyzers and is actively pursuing Alzheimer's blood-based diagnostics. They represent an emerging IVD platform competitor pursuing the same clinical market as ALZpath-licensed assays.
  • ADx NeuroSciences: ADx NeuroSciences is a biomarker-focused company developing assays and reagents for neurodegenerative disease diagnostics. It operates in the same antibody/biomarker infrastructure layer as ALZpath and supplies major IVD players including Fujirebio.
  • MagQu Co., Ltd. MagQu develops immunomagnetic reduction (IMR) technology for ultra-sensitive blood-based detection of biomarkers including those for Alzheimer's disease (e.g., Aβ42, tau). Comparable as an emerging diagnostic technology platform targeting the same AD blood-test market.

Others

  • Bio-Techne: Bio-Techne is both an ALZpath licensing partner (Ella/Simple Plex platform) and a major supplier of research-use-only antibodies and immunoassay reagents. It functions as a complementary ecosystem participant rather than a direct diagnostic competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

ALZpath social profiles

Digital presence

ALZpath compliance and trust

Trust signal

Compliance1 record

ALZpath financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ALZpath leadership team

Management profile

Number of profiles

Profiles18 records

ALZpath funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ALZpath M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALZpath

What does ALZpath do?

ALZpath develops and commercializes a proprietary monoclonal pTau217 antibody that enables blood-based detection of Alzheimer's disease pathology up to 15 years before symptoms appear. The company licenses this antibody to leading in vitro diagnostic companies (Abbott, Roche, Siemens Healthineers, Beckman Coulter) for integration into their immunoassay platforms, and offers ALZpathDx as a laboratory developed test through Neurocode. The antibody achieves AUC values of 0.92-0.97 for detecting amyloid and tau pathology, matching the performance of PET imaging and cerebrospinal fluid testing.

Is ALZpath a public or private company?

ALZpath is a private company. It is classified as unknown and is currently operating.

When was ALZpath founded?

ALZpath was founded in 2020. It employs 1 to 10 people.

Where is ALZpath based?

ALZpath is headquartered in Carlsbad, United States, in the North America region.

How does ALZpath make money?

Four revenue lines are on record. Antibody Licensing is the primary driver. The others are laboratory Developed Test (LDT) Services, grant Funding and research Use Only (RUO) Reagent Sales.

Who are ALZpath's main competitors?

Direct peers on record are C2N Diagnostics, Fujirebio, Quanterix and Araclon Biotech (Grifols). Broad incumbents are Eli Lilly and Roche Diagnostics. Emerging players are Sysmex, ADx NeuroSciences and MagQu Co., Ltd.. Bio-Techne is listed as an others.

Does ALZpath have an API?

No public API is recorded for ALZpath.

What industry is ALZpath in?

ALZpath's product category is Alzheimer's Disease Diagnostics. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Yahoo/C O R R E C T I O N -- ALZpath, Inc./ALZpath and Quanterix expanded their licensing agreement to use ALZpath's pTau217 antibody on Quanterix's Simoa platform. The assay has appeared in 161 peer-reviewed publications, and a December 2025 Nature study used it to assess Alzheimer's prevalence. The expansion aims to support emerging biomarker research.WebProNewsFDA Clears pTau217 Blood Test for Early Alzheimer’s Detection in Adults 40+The FDA has cleared ALZpath's pTau217 blood test, which measures phosphorylated tau at position 217 to detect Alzheimer's pathology in adults 40 and older, replacing PET scans or lumbar punctures. Studies show accuracy often exceeding 90% against fluid or imaging biomarkers, with list prices around $400 to $500. Quest Diagnostics and Labcorp plan commercial offerings, and point-of-care versions are in development.PR NewswireALZpath Broadens Strategic Agreement with Alamar Biosciences to Advance Clinical Diagnostics for Alzheimer's DiseaseALZpath, Inc. announced the expansion of its strategic agreement with Alamar Biosciences, granting Alamar commercial rights to utilize ALZpath's proprietary pTau217 antibody in blood-based diagnostic tests intended for clinical use. The expanded collaboration builds on an initial February 2024 agreement that covered research use only assays, and now enables Alamar and its customers to develop IVD (in vitro diagnostic) assays for Alzheimer's disease testing. The announcement was made during the ADLM Annual Meeting, coinciding with significant industry momentum as the pTau217 biomarker continues to gain rapid adoption worldwide for Alzheimer's disease detection.AijournALZpath Demonstrates Global Clinical Impact at AAIC 2026, with Proprietary pTau217 Antibody Anchoring 86 Presentations Demonstrating Clinical and Diagnostic Value Across the Translational PipelineALZpath, Inc. announced that its proprietary pTau217 antibody will be featured in 86 scientific presentations at the Alzheimer's Association International Conference (AAIC) in London from July 12-15, 2026, representing adoption across 56 academic, clinical, and industry organizations. The antibody has been featured in 219 peer-reviewed publications since its 2023 launch and has been selected by Abbott, Beckman-Coulter Diagnostics, Roche, Siemens Healthineers, Alamar Biosciences, Bio-Techne, and Quanterix for developing research and clinical pTau217 diagnostic assays. The conference presentations demonstrate the antibody's expanding role as a diagnostic cornerstone for Alzheimer's disease blood-based biomarker research, clinical trials, and patient care applications worldwide.PR NewswireALZpath Demonstrates Global Clinical Impact at AAIC 2026, with Proprietary pTau217 Antibody Anchoring 86 Presentations Demonstrating Clinical and Diagnostic Value Across the Translational PipelineALZpath, Inc. announced that its proprietary pTau217 antibody will be featured in 86 scientific presentations at the Alzheimer's Association International Conference (AAIC) 2026 in London from July 12-15, with contributions from 56 academic, clinical, and industry organizations. The antibody, launched in 2023 and now featured in 219 peer-reviewed publications, has been selected by major diagnostic companies including Abbott, Beckman-Coulter Diagnostics, Roche, Siemens Healthineers, Alamar Biosciences, Bio-Techne, and Quanterix for development of research and clinical pTau217 assays. The presentations span nine scientific themes and further establish the antibody as a diagnostic cornerstone for Alzheimer's disease research and clinical applications worldwide.AdvfnALZpath Demonstrates Global Clinical Impact at AAIC 2026, with Proprietary pTau217 Antibody Anchoring 86 Presentations Demonstrating Clinical and Diagnostic Value Across the Translational PipelineALZpath, Inc. announced that its proprietary pTau217 antibody will be featured in 86 scientific presentations from 56 leading academic, clinical, and industry organizations at the Alzheimer's Association International Conference (AAIC) in London from July 12-15, 2026. Since its 2023 launch, the antibody has been featured in 219 peer-reviewed publications and has been selected by Abbott, Beckman-Coulter Diagnostics, Roche, Siemens Healthineers, Alamar Biosciences, Bio-Techne, and Quanterix for developing pTau217 diagnostic assays. The growing adoption across the translational pipeline underscores the antibody's role as a diagnostic cornerstone for Alzheimer's disease research and clinical applications.Simply Wall StHow An ALZpath Alzheimer’s Test Deal And Dividend Streak At Abbott (ABT) Has Changed Its Investment StoryIn June 2026, Abbott's board declared a quarterly dividend of $0.63 per share, representing the company's 410th consecutive quarterly payout since 1924, while simultaneously ALZpath licensed its proprietary pTau217 antibody to Abbott for a blood-based Alzheimer’s diagnostic test on the Alinity ci-series systems. The dividend milestone underscores Abbott’s long-standing commitment to shareholder returns, while the ALZpath deal represents incremental innovation in the diagnostics segment. The article frames both developments as part of Abbott’s broader investment narrative, balanced against ongoing pricing and policy uncertainty in China’s diagnostics market.Investing.comALZpath licenses Alzheimer’s antibody to Abbott for diagnostic test By Investing.comALZpath Inc. announced a licensing agreement with Abbott to incorporate its phosphorylated Tau 217 (pTau217) antibody into an in vitro diagnostic test for Alzheimer's disease, designed for use on Abbott's Alinity ci-series systems. The test will leverage blood-based biomarkers as a less costly and invasive alternative to PET imaging and cerebrospinal fluid analysis for Alzheimer's detection. Financial terms of the agreement were not disclosed.Stock TitanALZpath licenses pTau217 antibody to AbbottALZpath Inc. announced a global licensing agreement with Abbott to incorporate ALZpath's proprietary phosphorylated Tau 217 (pTau217) antibody into Abbott's development of an in vitro diagnostic test for Alzheimer's disease. The test would be designed for use on Abbott's Alinity ci-series systems, one of the largest install bases of immunoassay instruments worldwide. As disease-modifying therapies expand, this partnership aims to enable earlier Alzheimer's diagnosis at scale through blood-based biomarkers as an alternative to costly PET imaging and invasive cerebrospinal fluid analysis.PR NewswireALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease TestingALZpath Inc. has signed a global licensing agreement with Abbott (NYSE: ABT) to incorporate ALZpath's proprietary phosphorylated Tau 217 (pTau217) antibody into Abbott's development of an in vitro diagnostic test for Alzheimer's disease. The test would be designed for use on Abbott's Alinity ci-series systems, with ALZpath's antibody backed by more than 200 peer-reviewed publications across 18 countries, offering a scalable alternative to costly PET imaging and cerebrospinal fluid analysis. The partnership aims to enable high-performance blood-based testing to reach clinicians and patients globally as disease-modifying therapies continue to expand.